Identification

Name
Hydrocodone
Accession Number
DB00956  (APRD00591, DB09475)
Type
Small Molecule
Groups
Approved, Illicit
Description

Narcotic analgesic related to codeine, but more potent and more addicting by weight. It is used also as cough suppressant.

Structure
Thumb
Synonyms
  • (-)-Dihydrocodeinone
  • 4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one
  • Dihydrocodeinone
  • Hidrocodona
  • Hydrocodon
  • Hydrocodone polistirex
  • Hydrocodonum
  • Hydrocone
  • Hydroconum
  • Idrocodone
External IDs
NSC-19044
Product Ingredients
IngredientUNIICASInChI Key
Hydrocodone bitartrateNO70W886KK34195-34-1JMBRWJAVUIITGV-LNNMZZBZSA-N
Hydrocodone hydrochlorideQKZ0920OV325968-91-6GCJAEXSZUXBMFS-RNWHKREASA-N
Hydrocodone polistirexNot AvailableNot AvailableNot applicable
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hycodan SyrupSyrup5 mgOralBristol Myers Squibb1992-12-31Not applicableCanada
Hycodan TabletsTablet5 mgOralBristol Myers Squibb1992-12-31Not applicableCanada
Hysingla ERTablet, extended release80 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release30 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release120 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release60 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release20 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release100 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERTablet, extended release40 mg/1OralPurdue Pharma LP2015-01-15Not applicableUs
Pdp-hydrocodoneSyrup5 mgOralPendopharm Division Of De Pharmascience Inc2009-03-21Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Caldomine Dh AdulteHydrocodone bitartrate (5 mg) + Pyrilamine maleate (12.5 mg) + Pheniramine maleate (12.5 mg) + Phenylpropanolamine hydrochloride (25 mg)LiquidOralTechnilab Pharma Inc.1981-12-312001-04-04Canada
Caldomine Dh EnfantHydrocodone bitartrate (1.667 mg) + Pyrilamine maleate (6.25 mg) + Pheniramine maleate (6.25 mg) + Phenylpropanolamine hydrochloride (12.5 mg)LiquidOralTechnilab Pharma Inc.1982-12-312001-04-04Canada
CodofenHydrocodone bitartrate (7.5 mg) + Ibuprofen (200 mg)TabletOralPaladin Labs IncNot applicableNot applicableCanada
Coristine-DH LiqHydrocodone bitartrate (1.7 mg) + Phenylephrine hydrochloride (10 mg)SyrupOralTechnilab Pharma Inc.1988-12-312006-07-28Canada
DalmacolHydrocodone bitartrate (1.65 mg) + Doxylamine succinate (6 mg) + Etafedrine hydrochloride (16.65 mg) + Ethanol (0.25 ml) + Sodium Citrate (200 mg)SyrupOralLaboratoire Atlas Inc1983-12-31Not applicableCanada
DalmacolHydrocodone bitartrate (1.65 mg) + Doxylamine succinate (6 mg) + Etafedrine hydrochloride (16.65 mg) + Ethanol (0.25 ml) + Sodium Citrate (200 mg)SyrupOralLaboratoire Riva Inc1997-03-26Not applicableCanada
Dimetane Expectorant DcHydrocodone bitartrate (1.8 mg) + Brompheniramine maleate (2 mg) + Guaifenesin (100 mg) + Phenylephrine hydrochloride (5 mg)SyrupOralPfizer Laboratories Div Pfizer Inc.2001-09-06Not applicableCanada
Dimetane Expectorant-DC SyrHydrocodone bitartrate (1.8 mg) + Brompheniramine maleate (2 mg) + Guaifenesin (100 mg) + Phenylephrine hydrochloride (5 mg) + Phenylpropanolamine hydrochloride (5 mg)SyrupOralWhitehall Robins Inc.1993-12-312001-04-10Canada
FlowtussHydrocodone bitartrate (2.5 mg/5mL) + Guaifenesin (200 mg/5mL)LiquidOralMission Pharmacal2015-08-18Not applicableUs
HycetHydrocodone bitartrate (7.5 mg/15mL) + Acetaminophen (325 mg/15mL)SyrupOralEclat Pharmaceuticals, LLC2011-08-012015-12-29Us
Categories
UNII
6YKS4Y3WQ7
CAS number
125-29-1
Weight
Average: 299.3642
Monoisotopic: 299.152143543
Chemical Formula
C18H21NO3
InChI Key
LLPOLZWFYMWNKH-CMKMFDCUSA-N
InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
IUPAC Name
(1S,5R,13R,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][[email protected]@]12OC3=C(OC)C=CC4=C3[[email protected]@]11CCN(C)[[email protected]]([H])(C4)[[email protected]]1([H])CCC2=O

Pharmacology

Indication

For relief of moderate to moderately severe pain. Also used for the symptomatic relief of nonproductive cough, alone or in combination with other antitussives or expectorants.

Structured Indications
Pharmacodynamics

Hydrocodone, a semisynthetic opiate agonist and hydrogenated ketone derivative, is similar to other phenanthrene derivatives, such as codeine. Used as an analgesic, hydrocodone is combined with acetaminophen, ibuprofen, or aspirin to treat pain. Used as an antitussive, hydrocodone is combined with phenylephrine, pseudoephedrine, phenylpropanolamine, guaifenesin, pyrilamine, pheniramine, or chlorpheniramine. Opiate agonists exert their principal pharmacologic effect at specific receptor binding sites in the CNS and other tissues. There are several subtypes of opiate receptors including the mu receptor (localized in pain modulating regions of the CNS), the kappa receptor (localized in the deep layers of the cerebral cortex), the delta receptor (localized in the limbic regions of the CNS), and the sigma receptor (thought to mediate the dysphoric and psychotomimetic effects of some opiate partial agonists). Agonist activity at the mu or kappa receptor can result in analgesia, miosis, and/or decreased body temperature. Agonist activity at the mu receptor can also result in suppression of opiate withdrawal, whereas antagonist activity can result in precipitation of withdrawal. Opiate agonists act at several sites within the CNS involving several systems of neurotransmitters to produce analgesia, but the precise mechanism of action has not been fully determined. Opiate agonists do not alter the threshold or responsiveness of afferent nerve endings to noxious stimuli nor the conduction of impulses along peripheral nerves. Instead, they alter the perception of pain at the spinal cord and higher levels in the CNS and the person's emotional response to pain.

Mechanism of action

Hydrocodone acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Hydrocodone primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as hydrocodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
ADelta-type opioid receptor
agonist
Human
Absorption

Well absorbed from the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding

As most agents in the 5-ring morphinan group of semi-synthetic opioids bind plasma protein to a similar degree (range 19% [hydromorphone] to 45% [oxycodone]), hydrocodone is expected to fall within this range.

Metabolism

Hepatic and also in intestinal mucosa.

Route of elimination
Not Available
Half life

1.25-3 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, dizziness, ringing in the ears, confusion, blurred vision, eye problems, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdose, apnea, circulatory collapse, cardiac arrest and death may occur. LD50=85.7mg/kg (subcutaneous, in mice).

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Hydrocodone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Hydrocodone.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Hydrocodone.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Hydrocodone.Experimental, Illicit
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Hydrocodone.Experimental
AbirateroneThe serum concentration of Hydrocodone can be increased when it is combined with Abiraterone.Approved
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Hydrocodone.Approved
AdipiplonAdipiplon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
AlaproclateHydrocodone may increase the serotonergic activities of Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Hydrocodone.Experimental
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Hydrocodone.Approved, Vet Approved
AllopregnanoloneAllopregnanolone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
AlphaprodineAlphaprodine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Amiloride.Approved
AmiodaroneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Amiodarone resulting in a loss in efficacy.Approved, Investigational
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Hydrocodone which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Hydrocodone.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Hydrocodone.Approved
AprepitantThe serum concentration of Hydrocodone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ArtemetherThe metabolism of Hydrocodone can be decreased when combined with Artemether.Approved
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AtazanavirThe serum concentration of Hydrocodone can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Hydrocodone can be increased when it is combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Hydrocodone.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hydrocodone.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Hydrocodone.Approved, Vet Approved
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational, Vet Approved
AzelastineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
AzosemideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Azosemide.Investigational
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Hydrocodone.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Hydrocodone.Withdrawn
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Hydrocodone.Approved
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BetaxololThe metabolism of Hydrocodone can be decreased when combined with Betaxolol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Hydrocodone.Approved, Investigational
BL-1020BL-1020 may increase the hypotensive activities of Hydrocodone.Investigational
BoceprevirThe serum concentration of Hydrocodone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Hydrocodone.Experimental
BortezomibThe serum concentration of Hydrocodone can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Hydrocodone can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Hydrocodone.Experimental
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
BromisovalBromisoval may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
BromperidolBromperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bumetanide.Approved
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Bupropion resulting in a loss in efficacy.Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Hydrocodone.Approved, Vet Approved
CanertinibCanertinib may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
Canrenoic acidThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Canrenone.Investigational
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit, Investigational, Vet Approved
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Hydrocodone.Withdrawn
CelecoxibThe metabolism of Hydrocodone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Hydrocodone can be increased when it is combined with Ceritinib.Approved
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ChloroquineThe metabolism of Hydrocodone can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydrocodone.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Hydrocodone.Illicit, Withdrawn
ChlorproethazineChlorproethazine may increase the hypotensive activities of Hydrocodone.Experimental
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorthalidone.Approved
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CholecalciferolThe metabolism of Hydrocodone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cicletanine.Investigational
CimetidineThe metabolism of Hydrocodone can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Cinacalcet resulting in a loss in efficacy.Approved
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
CitalopramThe metabolism of Hydrocodone can be decreased when combined with Citalopram.Approved
ClarithromycinThe serum concentration of Hydrocodone can be increased when it is combined with Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ClofenamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clofenamide.Experimental
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ClopamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clopamide.Experimental
ClopenthixolClopenthixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ClorexoloneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clorexolone.Experimental
ClothiapineClothiapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
ClotrimazoleThe serum concentration of Hydrocodone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CobicistatThe serum concentration of Hydrocodone can be increased when it is combined with Cobicistat.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
ConivaptanThe serum concentration of Hydrocodone can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Hydrocodone can be increased when it is combined with Crizotinib.Approved
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
CyclopenthiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cyclopenthiazide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hydrocodone.Approved
CyclosporineThe serum concentration of Hydrocodone can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cyclothiazide.Approved
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DabrafenibThe serum concentration of Hydrocodone can be decreased when it is combined with Dabrafenib.Approved
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DapoxetineHydrocodone may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe metabolism of Hydrocodone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Hydrocodone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Hydrocodone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Hydrocodone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Hydrocodone can be increased when it is combined with Delavirdine.Approved
DeramciclaneDeramciclane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin.Approved
DesvenlafaxineHydrocodone may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Hydrocodone.Withdrawn
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydrocodone.Approved
Diethyl etherDiethyl ether may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
DiethylpropionDiethylpropion may increase the analgesic activities of Hydrocodone.Approved, Illicit
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DihydroergotamineThe serum concentration of Hydrocodone can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DiltiazemThe serum concentration of Hydrocodone can be increased when it is combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DixyrazineDixyrazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
DosulepinThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Dosulepin resulting in a loss in efficacy.Approved
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
DoxycyclineThe serum concentration of Hydrocodone can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
DronedaroneThe serum concentration of Hydrocodone can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Drospirenone.Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
DuloxetineThe metabolism of Hydrocodone can be decreased when combined with Duloxetine.Approved
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Illicit
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Efonidipine.Approved, Investigational
EliglustatThe metabolism of Hydrocodone can be decreased when combined with Eliglustat.Approved
EltanoloneEltanolone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
EluxadolineHydrocodone may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Hydrocodone.Experimental
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
EnzalutamideThe serum concentration of Hydrocodone can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Eplerenone.Approved
ErythromycinThe serum concentration of Hydrocodone can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramHydrocodone may increase the serotonergic activities of Escitalopram.Approved, Investigational
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Etacrynic acid.Approved
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Hydrocodone.Experimental
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Hydrocodone.Approved
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
Ethyl chlorideEthyl chloride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental, Investigational
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational, Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
EtoperidoneHydrocodone may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Hydrocodone.Experimental
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Withdrawn
FenquizoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fenquizone.Experimental
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydrocodone.Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FluanisoneFluanisone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
FluconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Fluconazole.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
FluoxetineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Fluoxetine resulting in a loss in efficacy.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Fluticasone propionateFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
FosamprenavirThe serum concentration of Hydrocodone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Hydrocodone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Hydrocodone.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Hydrocodone can be increased when it is combined with Fusidic Acid.Approved
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Gabapentin EnacarbilGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Hydrocodone.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Hydrocodone.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
GepefrineGepefrine may increase the analgesic activities of Hydrocodone.Experimental
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Hydrocodone.Approved, Investigational, Vet Approved
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Hydrocodone.Experimental
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Hydrocodone.Experimental
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Hydrocodone.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Hydrocodone.Experimental
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydroflumethiazide.Approved, Investigational
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may increase the analgesic activities of Hydrocodone.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hydrocodone.Approved
IbopamineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ibopamine.Experimental
IdelalisibThe serum concentration of Hydrocodone can be increased when it is combined with Idelalisib.Approved
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ImatinibThe serum concentration of Hydrocodone can be increased when it is combined with Imatinib.Approved
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
IndalpineHydrocodone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Indapamide.Approved
IndinavirThe serum concentration of Hydrocodone can be increased when it is combined with Indinavir.Approved
IndiplonIndiplon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
Iofetamine I-123Iofetamine I-123 may increase the analgesic activities of Hydrocodone.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydrocodone.Approved
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Hydrocodone.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Hydrocodone.Withdrawn
IsavuconazoniumThe serum concentration of Hydrocodone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Hydrocodone.Approved
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
IsoniazidThe metabolism of Hydrocodone can be decreased when combined with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Isosorbide.Approved, Investigational
IsradipineThe serum concentration of Hydrocodone can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Hydrocodone can be increased when it is combined with Ivacaftor.Approved
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
KetoconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
LevomilnacipranHydrocodone may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Hydrocodone.Approved, Investigational
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit
LopinavirThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Lopinavir resulting in a loss in efficacy.Approved
LoprazolamLoprazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LorcaserinThe metabolism of Hydrocodone can be decreased when combined with Lorcaserin.Approved
LormetazepamLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LovastatinThe serum concentration of Hydrocodone can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
LuliconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Hydrocodone can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Hydrocodone can be decreased when combined with Lumefantrine.Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ManidipineThe metabolism of Hydrocodone can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mannitol.Approved, Investigational
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Hydrocodone.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Hydrocodone.Withdrawn
MebicarMebicar may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MebutizideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mebutizide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydrocodone.Approved
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MedazepamMedazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
MefrusideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mefruside.Experimental
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MephedroneMephedrone may increase the analgesic activities of Hydrocodone.Investigational
MephentermineMephentermine may increase the analgesic activities of Hydrocodone.Approved
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
MeptazinolMeptazinol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
MersalylThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mersalyl.Approved
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Hydrocodone.Approved, Investigational
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methazolamide.Approved
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MethotrimeprazineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may increase the analgesic activities of Hydrocodone.Experimental
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methyclothiazide.Approved
MethylecgonineMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Hydrocodone.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Hydrocodone.Approved
MeticraneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Meticrane.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Hydrocodone.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Metolazone.Approved
MetoprololThe metabolism of Hydrocodone can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineHydrocodone may increase the sedative activities of Metyrosine.Approved
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
MidomafetamineMidomafetamine may increase the analgesic activities of Hydrocodone.Experimental, Illicit, Investigational
MidostaurinThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Midostaurin resulting in a loss in efficacy.Approved
MifepristoneThe serum concentration of Hydrocodone can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranHydrocodone may increase the serotonergic activities of Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Hydrocodone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MirabegronThe metabolism of Hydrocodone can be decreased when combined with Mirabegron.Approved
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MitotaneThe serum concentration of Hydrocodone can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Hydrocodone.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Hydrocodone.Approved
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
MoricizineMoricizine may increase the hypotensive activities of Hydrocodone.Approved, Investigational, Withdrawn
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
MuzolimineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Muzolimine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
NaltrexoneThe therapeutic efficacy of Hydrocodone can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe serum concentration of Hydrocodone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Hydrocodone can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Hydrocodone can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Hydrocodone can be increased when it is combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Hydrocodone.Withdrawn
NicardipineThe metabolism of Hydrocodone can be decreased when combined with Nicardipine.Approved
NilotinibThe serum concentration of Hydrocodone can be increased when it is combined with Nilotinib.Approved, Investigational
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
NorfluraneNorflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Hydrocodone.Withdrawn
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
OlaparibThe serum concentration of Hydrocodone can be increased when it is combined with Olaparib.Approved
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
OrphenadrineOrphenadrine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
OsimertinibThe serum concentration of Hydrocodone can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Hydrocodone.Experimental, Investigational
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OxethazaineOxethazaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Hydrocodone.Investigational
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydrocodone.Approved, Investigational
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Hydrocodone.Approved
PalbociclibThe serum concentration of Hydrocodone can be increased when it is combined with Palbociclib.Approved
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PamabromThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pamabrom.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Hydrocodone.Approved
PanobinostatThe serum concentration of Hydrocodone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeParaldehyde may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Hydrocodone.Approved
ParoxetineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Paroxetine resulting in a loss in efficacy.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Hydrocodone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.Approved
PenfluridolPenfluridol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Hydrocodone.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PhenazocinePhenazocine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Hydrocodone.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Hydrocodone.Experimental
PhenibutPhenibut may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Hydrocodone.Withdrawn
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PhenoperidinePhenoperidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Hydrocodone.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Hydrocodone.Approved, Illicit
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydrocodone.Approved
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydrocodone.Approved
PiretanideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Piretanide.Experimental
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Hydrocodone.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Hydrocodone.Withdrawn
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Polythiazide.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PosaconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleHydrocodone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hydrocodone.Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
PropanididPropanidid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Hydrocodone.Approved
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
PropericiazinePropericiazine may increase the hypotensive activities of Hydrocodone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Hydrocodone.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Hydrocodone.Approved, Investigational
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ProxibarbalProxibarbal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Hydrocodone.Approved
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Quinethazone.Approved
QuinidineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Quinidine resulting in a loss in efficacy.Approved
QuinineThe metabolism of Hydrocodone can be decreased when combined with Quinine.Approved
QuinisocaineQuinisocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
RamosetronHydrocodone may increase the constipating activities of Ramosetron.Approved, Investigational
RanolazineThe serum concentration of Hydrocodone can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Hydrocodone.Approved
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
RifabutinThe serum concentration of Hydrocodone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Hydrocodone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Hydrocodone can be decreased when it is combined with Rifapentine.Approved
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
RitobegronRitobegron may increase the analgesic activities of Hydrocodone.Investigational
RitonavirThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Ritonavir resulting in a loss in efficacy.Approved, Investigational
RolapitantThe metabolism of Hydrocodone can be decreased when combined with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Rolofylline.Investigational
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
RopiniroleHydrocodone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
RotigotineHydrocodone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Hydrocodone.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Hydrocodone.Withdrawn
SaquinavirThe serum concentration of Hydrocodone can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Hydrocodone.Approved, Investigational, Vet Approved
SepranoloneSepranolone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
SertralineThe metabolism of Hydrocodone can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
SildenafilThe serum concentration of Hydrocodone can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Hydrocodone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Hydrocodone can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Hydrocodone.Approved
SpiradolineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Spiradoline.Investigational
SpironolactoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Hydrocodone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Hydrocodone.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
SulfisoxazoleThe serum concentration of Hydrocodone can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
SultoprideSultopride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
SuvorexantSuvorexant may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TelaprevirThe serum concentration of Hydrocodone can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Hydrocodone can be increased when it is combined with Telithromycin.Approved
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TerbinafineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Terbinafine resulting in a loss in efficacy.Approved, Investigational, Vet Approved
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Investigational
ThalidomideThalidomide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Theobromine.Approved, Investigational
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Hydrocodone.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Hydrocodone.Withdrawn
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Hydrocodone.Approved
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TiclopidineThe serum concentration of Hydrocodone can be increased when it is combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ticrynafen.Withdrawn
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
TilidineTilidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Hydrocodone.Approved
TipranavirThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Tipranavir resulting in a loss in efficacy.Approved, Investigational
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TocilizumabThe serum concentration of Hydrocodone can be decreased when it is combined with Tocilizumab.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Hydrocodone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Hydrocodone.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tolvaptan.Approved
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TorasemideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide.Approved
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Triamterene.Approved
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Tricaine methanesulfonateTricaine methanesulfonate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneTrichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TrifluperidolTrifluperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hydrocodone.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydrocodone.Approved, Investigational
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Hydrocodone.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Hydrocodone.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Hydrocodone.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Hydrocodone.Approved
UlaritideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Hydrocodone.Approved
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hydrocodone.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Hydrocodone.Approved
VenlafaxineThe serum concentration of Hydrocodone can be increased when it is combined with Venlafaxine.Approved
VeraliprideVeralipride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
VerapamilThe serum concentration of Hydrocodone can be increased when it is combined with Verapamil.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
Vinyl etherVinyl ether may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
VoriconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
XenonXenon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Experimental
XipamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Xipamide.Experimental
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZimelidineHydrocodone may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Vet Approved
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.
  • To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).

References

Synthesis Reference

Anne M. Hailes, Christopher E. French, Neil C. Bruce, "Morphinone reductase for the preparation of hydromorphone and hydrocodone." U.S. Patent US5571685, issued November, 1990.

US5571685
General References
Not Available
External Links
Human Metabolome Database
HMDB15091
KEGG Drug
D08045
KEGG Compound
C08024
PubChem Compound
5284569
PubChem Substance
46506225
ChemSpider
4447623
BindingDB
50386689
ChEBI
5779
ChEMBL
CHEMBL1457
Therapeutic Targets Database
DAP000253
PharmGKB
PA449900
RxList
RxList Drug Page
Wikipedia
Hydrocodone
ATC Codes
R05DA03 — Hydrocodone
AHFS Codes
  • 48:08.00 — Antitussives
MSDS
Download (48.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentFracture, Ankle1
0WithdrawnTreatmentPain / Painful musculoskeletal conditions1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHepatic Impairment1
1CompletedNot AvailableImpaired Renal Function1
1CompletedNot AvailablePain1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedTreatmentDrug Abuse1
1RecruitingTreatmentHead and Neck Carcinoma / Oral Mucositis1
1WithdrawnTreatmentOpioid-Related Disorders / Pain, Acute / Postoperative pain2
2CompletedNot AvailableDegenerative Joint Disease1
2CompletedNot AvailablePostoperative pain1
2CompletedTreatmentChronic Low Back Pain (CLBP)1
2CompletedTreatmentOpioid-Related Disorders1
2CompletedTreatmentPain6
2Not Yet RecruitingTreatmentPain1
2Not Yet RecruitingTreatmentPainful musculoskeletal conditions1
2RecruitingTreatmentCorneal Abrasions / Eye Trauma1
3CompletedPreventionNausea / Pain / Vomiting1
3CompletedSupportive CareAnalgesia After ED Discharge for Extremity Injuries1
3CompletedTreatmentBack Pain Lower Back Chronic1
3CompletedTreatmentChronic Low Back Pain (CLBP)4
3CompletedTreatmentChronic Nonmalignant and Nonneuropathic Pain1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentModerate to Severe Chronic, Non-malignant Pain1
3CompletedTreatmentNausea / Pain / Vomiting1
3CompletedTreatmentOsteoarthritis (OA)1
3CompletedTreatmentPain3
3CompletedTreatmentPain, Chronic1
3RecruitingSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3TerminatedNot AvailablePost Operative Pain1
4CompletedNot AvailablePain, Chronic1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Vascular / Dementias / Pain1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentPain1
4CompletedTreatmentToothache1
4Enrolling by InvitationTreatmentCarpal Tunnel / Cystic tumour of the ganglia / De Quervain's Disease / Trigger Finger1
4Not Yet RecruitingTreatmentPain1
4RecruitingSupportive CareCarpal Tunnel1
4RecruitingSupportive CareColon Diverticulosis / Colonic Neoplasms / Constipation Drug Induced / Diverticulitis, Colonic / Ileus / Ileus paralytic / Ileus; Mechanical / Malignant Neoplasm of Colon / Occasional Constipation / Postoperative pain / Rectum Cancer / Rectum Neoplasm1
4RecruitingTreatmentBody Weight Changes / Postoperative Hemorrhages / Postoperative pain / Prophylaxis against postoperative nausea and vomiting1
4RecruitingTreatmentPain2
4RecruitingTreatmentPain Management1
4SuspendedTreatmentRotator Cuff Syndrome1
4TerminatedTreatmentAdverse Reaction to Drug / Obstructive Sleep Apnea (OSA) / Recurrent Tonsillitis / Sleep Disordered Breathing (SDB)1
4TerminatedTreatmentCarpal Tunnel Syndrome (CTS)1
Not AvailableCompletedTreatmentCancer, Breast / Postoperative pain1
Not AvailableCompletedTreatmentChildren / Laceration / Pain / Procedures1
Not AvailableCompletedTreatmentContraception / Inhalation of Nitrous Oxide1
Not AvailableCompletedTreatmentDrug Interactions1
Not AvailableCompletedTreatmentSkin Laxity1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableUnknown StatusNot AvailableAnalgesic Response1
Not AvailableWithdrawnSupportive CareToothache1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
LiquidOral
TabletOral5 mg
SolutionOral
TabletOral
Suspension, extended releaseOral
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral120 mg/1
Tablet, extended releaseOral20 mg/1
Tablet, extended releaseOral30 mg/1
Tablet, extended releaseOral40 mg/1
Tablet, extended releaseOral60 mg/1
Tablet, extended releaseOral80 mg/1
SyrupOral
SyrupOral5 mg
SyrupOral1 mg
Kit
CreamTopical
Capsule, extended releaseOral
SuspensionOral
Tablet, extended releaseOral
Tablet, coatedOral
Tablet, film coatedOral
Capsule, extended releaseOral10 mg/1
Capsule, extended releaseOral15 mg/1
Capsule, extended releaseOral20 mg/1
Capsule, extended releaseOral30 mg/1
Capsule, extended releaseOral40 mg/1
Capsule, extended releaseOral50 mg/1
Prices
Unit descriptionCostUnit
Hydrocodone-Acetaminophen 7.5-500 mg/15ml Solution 473ml Bottle60.97USD bottle
Hydrocodone-Ibuprofen 7.5-200 mg tablet1.13USD tablet
Hydrocodone-Acetaminophen 10-750 mg tablet1.1USD tablet
Hydrocodone-Acetaminophen 7.5-325 mg tablet0.63USD tablet
Hydrocodone-Acetaminophen 10-325 mg tablet0.57USD tablet
Hydrocodone-Acetaminophen 5-325 mg tablet0.57USD tablet
Hydrocodone-Acetaminophen 10-660 mg tablet0.53USD tablet
Hydrocodone-Acetaminophen 10-500 mg tablet0.5USD tablet
Hydrocodone-Acetaminophen 10-650 mg tablet0.47USD tablet
Hydrocodone-Acetaminophen 7.5-500 mg tablet0.47USD tablet
Hydrocodone-Acetaminophen 2.5-500 mg tablet0.43USD tablet
Hydrocodone-Acetaminophen 7.5-750 mg tablet0.43USD tablet
Hydrocodone-Acetaminophen 5-500 mg tablet0.4USD tablet
Hydrocodone-Acetaminophen 7.5-650 mg tablet0.16USD tablet
Hydrocodone-Homatropine 5-1.5 mg/5ml Syrup0.15USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9265760No2013-07-232033-07-23Us
US6599531No1997-06-102017-06-10Us
US6348216No1997-06-102017-06-10Us
US6228398No1999-11-012019-11-01Us
US8309060No2003-11-202023-11-20Us
US6488963No1997-06-242017-06-24Us
US9060940No2001-10-302021-10-30Us
US8808740No2011-12-212031-12-21Us
US6733783No2001-10-302021-10-30Us
US9095614No2007-08-242027-08-24Us
US9095615No2007-08-242027-08-24Us
US8361499No2001-10-302021-10-30Us
US9084816No2007-08-242027-08-24Us
US9205056No2001-10-302021-10-30Us
US8647667No2001-10-302021-10-30Us
US9198863No2001-10-302021-10-30Us
US9289391No2001-10-302021-10-30Us
US9056052No2001-10-302021-10-30Us
US8529948No2002-08-062022-08-06Us
US8551520No2001-10-302021-10-30Us
US9023401No2001-10-302021-10-30Us
US9326982No2013-07-252033-07-25Us
US6902742No1999-11-012019-11-01Us
US9132096No2014-09-122034-09-12Us
US9492389No2007-08-242027-08-24Us
US9492391No2007-08-242027-08-24Us
US9549907No2015-11-132035-11-13Us
US9572804No2000-10-302020-10-30Us
US9669023No2000-10-302020-10-30Us
US9486412No2007-08-242027-08-24Us
US9669024No2000-10-302020-10-30Us
US9572779No2011-12-212031-12-21Us
US9486413No2007-08-242027-08-24Us
US9517236No2000-10-302020-10-30Us
US9492390No2007-08-242027-08-24Us
US9675611No2000-10-302020-10-30Us
US9682077No2000-10-302020-10-30Us
US9545380No2007-08-242027-08-24Us
US9333201No2013-07-252033-07-25Us
US9610286No2013-07-252033-07-25Us
US9452163No2014-09-122034-09-12Us
US9486451No2014-09-122034-09-12Us
US9339499No2013-07-252033-07-25Us
US9421200No2013-07-252033-07-25Us
US9433619No2013-07-252033-07-25Us
US9675610No2003-06-162023-06-16Us
US9572803No2007-09-132027-09-13Us
US9216176No2007-09-132027-09-13Us
US8445018No2009-07-312029-07-31Us
US9713611No2014-09-122034-09-12Us
US9763933No2007-08-242027-08-24Us
US9770416No2007-08-242027-08-24Us
US9775809No2007-08-242027-08-24Us
US9750703No2011-12-212031-12-21Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)198 °CPhysProp
water solubilityInsolubleNot Available
logP1.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.797 mg/mLALOGPS
logP2.13ALOGPS
logP1.96ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)18ChemAxon
pKa (Strongest Basic)8.61ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.74 m3·mol-1ChemAxon
Polarizability32.05 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9984
Caco-2 permeable+0.8621
P-glycoprotein substrateSubstrate0.8253
P-glycoprotein inhibitor IInhibitor0.6425
P-glycoprotein inhibitor IINon-inhibitor0.8664
Renal organic cation transporterInhibitor0.6604
CYP450 2C9 substrateNon-substrate0.8546
CYP450 2D6 substrateSubstrate0.8997
CYP450 3A4 substrateSubstrate0.8168
CYP450 1A2 substrateNon-inhibitor0.8207
CYP450 2C9 inhibitorNon-inhibitor0.9412
CYP450 2D6 inhibitorInhibitor0.6629
CYP450 2C19 inhibitorNon-inhibitor0.8402
CYP450 3A4 inhibitorNon-inhibitor0.7625
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8675
Ames testNon AMES toxic0.7735
CarcinogenicityNon-carcinogens0.9419
BiodegradationNot ready biodegradable0.984
Rat acute toxicity3.0914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9024
hERG inhibition (predictor II)Non-inhibitor0.8165
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10.3 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0005-6970000000-3ba3e105098639cd6091
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0009000000-f21858df54194757e2d9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0009000000-9b129b5d29df52345272
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0649000000-82623b23b75f0a0b232d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0920000000-b67ff5a32d0ddd40c4c7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-006t-0900000000-0277ba7435a4081ab333
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0g6v-0900000000-b335c52fad1274cd28cb

Taxonomy

Description
This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Morphinans
Sub Class
Not Available
Direct Parent
Morphinans
Alternative Parents
Phenanthrenes and derivatives / Isoquinolones and derivatives / Tetralins / Coumarans / Anisoles / Aralkylamines / Alkyl aryl ethers / Piperidines / Trialkylamines / Ketones
show 5 more
Substituents
Morphinan / Phenanthrene / Isoquinolone / Tetralin / Coumaran / Anisole / Alkyl aryl ether / Aralkylamine / Piperidine / Benzenoid
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heteropentacyclic compound (CHEBI:5779)

Targets

Details
1. Mu-type opioid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC: The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000 Feb;292(2):803-9. [PubMed:10640321]
  3. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16. [PubMed:16291875]
  4. Hennies HH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988 Jul;38(7):877-80. [PubMed:2849950]
  5. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4. [PubMed:14600248]
  6. Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL: Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl). 2010 Oct;212(2):193-203. doi: 10.1007/s00213-010-1942-4. Epub 2010 Jul 28. [PubMed:20665209]
  7. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr: The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008 Dec 1;98(3):191-202. doi: 10.1016/j.drugalcdep.2008.05.007. Epub 2008 Jul 7. [PubMed:18606504]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16. [PubMed:16291875]
  2. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4. [PubMed:14600248]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. [PubMed:14998425]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. [PubMed:14998425]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18